ArticlePharmaceuticals (Basel, Switzerland)2018

Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure.

Sally Miller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.